エキスパートQ&A：生成AIはいかにしてGVD制作の手間を省くか

GVD（Global Value Dossier）作成を強化するために生成AIを検討する製薬企業が増加するにつれ、ワークフローを合理化し、エビデンスを統合し、市場参入戦略を最適化する可能性が明らかになりつつあります。

AIがこのプロセスにどのような変革をもたらすかを理解するため、FirstWordはS3 Connected HealthのコンサルティングサービスプログラムマネージャーであるHany Mina氏に話を聞きました。

レポートの内容

• GVDの作成において生成AIは現在どのように利用されているか
• 従来のアプローチと比較して、生成AIはGVD作成プロセスにどのようなユニークな利点をもたらすか
• GVDを担当するメディカルライティングチームやマーケットアクセスチームにおいて、生成AIがワークフローを変革するか
• バリューナラティブ、クリニカルサマリー、経済モデリングデータなど、GVDの中核となるコンテンツの作成において、生成AIはどの程度効果的か
• 生成AIは特定の市場や読者向けにGVDをカスタマイズするのに役立つか
• GVD開発に生成AIを使用した場合、どのような時間やコストの削減が見られたか
• GVDにおいてデータの正確性を確保することは非常に重要だが、生成AIからのアウトプットを検証するにはどのような対策が必要か
• 異なる利害関係者向けにGVDの内容を調整するために、生成AIをどのように活用できるか
• GVDの生成をサポートするために、特定されたデータソースのみが接続され、正しいデータが消費されるように、生成AIへのデータ入力をどのように制御できるか
• 特に規制の厳しい市場において、GVDの厳しい規制基準を満たすために生成AIをどのように最適化できるか
• 今後5年間で、GVD作成に最も大きな影響を与えると予想される生成AIのイノベーション
• GVD作成における生成AIの全体像を考えて、他に追加することをお勧めするモジュールやソリューションはあるか
• GVD開発のために生成AIを検討し始めたばかりの企業にどのようなアドバイスをするか

As pharmas increasingly explore genAI to enhance global value dossier (GVD) creation, its potential to streamline workflows, synthesise evidence and optimise market access strategies is becoming more apparent.

To understand how AI is transforming this process, FirstWord spoke with Hany Mina, consulting services program manager at S3 Connected Health.

Key Questions Answered:

• How is genAI currently being used in GVD creation?
• What unique advantages does genAI bring to the process of creating GVDs compared with traditional approaches?
• Do you see genAI transforming workflows within the medical writing and market access teams responsible for GVDs?
• How effective is genAI in generating core GVD content, such as value narratives, clinical summaries and economic modelling data?
• Can genAI assist in tailoring GVDs for specific markets or audiences?
• What kind of time and cost-savings have you observed when using genAI for GVD development?
• Ensuring data accuracy is critical in a GVD. What measures are necessary to validate outputs from genAI?
• How can genAI be leveraged to tailor GVD content for different stakeholders?
• How can we control the data input to genAI to ensure only identified data sources are connected and correct data are consumed to support GVD generation?
• How can genAI be optimised to meet stringent regulatory standards in GVDs, especially in highly regulated markets?
• What innovations in genAI do you foresee having the biggest impact on GVD creation in the next five years?
• Thinking of the big picture for genAI in GVD creation, are there other modules or solutions you suggest adding?
• What advice would you give to companies just beginning to explore genAI for GVD development?

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.